SCHEMBL3582278

SCHEMBL3582278

CC(C)c1c(C(=O)N(C)Cc2ccccc2)[nH]c(C(N)=O)c1S(=O)(=O)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIMK2 P53671 2/20 0.40
HSP90AA1 P07900 1/20 0.40
TLR9 Q9NR96 1/20 0.39
TLR8 Q9NR97 1/20 0.39
TLR7 Q9NYK1 1/20 0.39
ABL1 P00519 1/20 0.39
LCK P06239 1/20 0.39
LIMK1 P53667 1/20 0.39
KMT2A Q03164 5/20 0.39
MEN1 O00255 3/20 0.39
LIPE Q05469 1/20 0.39
PIN1 Q13526 1/20 0.39
HPGD P15428 3/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
ALDH1A1 P00352 2/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3578424 0.87 LIPE (0.42) LIMK2KMT2AMEN1LIPEALDH1A1
SCHEMBL3586571 0.85 FFAR2 (0.33) LIMK2TLR9TLR8TLR7LIPE
SCHEMBL3587158 0.84 PDK1 (0.42) HSP90AA1TLR9TLR8TLR7ALDH1A1
SCHEMBL3586340 0.83 NAMPT (0.35) TLR8TLR7KMT2AMEN1
SCHEMBL3592689 0.82 NAMPT (0.34) TLR9TLR8TLR7KMT2AMEN1
SCHEMBL3579136 0.82 MAP2 (0.34) LIMK2KMT2AMEN1LIPEHPGD
SCHEMBL3579005 0.82 FFAR2 (0.36) TLR9TLR8TLR7
SCHEMBL13369339 0.82 BRD4 (0.42) LIMK2ABL1LCKLIMK1KMT2A
SCHEMBL3578521 0.81 FFAR2 (0.40) KMT2AMEN1HPGDCA12CA1
SCHEMBL3587755 0.81 FFAR2 (0.33) TLR9TLR8TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-05-06 US claimed
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed
EP-2076492-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Merck & Co., Inc. (US) 2009-07-08 EP disclosed
WO-2008054605-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS RTF1, RNGTT, POLR2E LIMK2 4227/4885HSP90AA1 3132/4885TLR9 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.